1. A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end‐stage renal disease requiring haemodialysis. (16th May 2016) Authors: Gupta, Neeraj; Hanley, Michael J.; Harvey, R. Donald; Badros, Ashraf; Lipe, Brea; Kukreti, Vishal; Berdeja, Jesus; Yang, Huyuan; Hui, Ai‐Min; Qian, Mark; Zhang, Xiaoquan; Venkatakrishnan, Karthik; Chari, Ajai Journal: British journal of haematology Issue: Volume 174:Number 5(2016) Page Start: 748 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A Phase 1 Drug‐Drug Interaction Study Between Brigatinib and the CYP3A Substrate Midazolam in Patients With ALK‐Positive or ROS1‐Positive Solid Tumors. (27th January 2023) Authors: Hanley, Michael J.; D'Arcangelo, Manolo; Felip, Enriqueta; Garrido, Pilar; Zhu, Jiaxi; Ye, Meng; Vranceanu, Florin; Gupta, Neeraj Journal: Journal of clinical pharmacology Issue: Volume 63:Number 5(2023) Page Start: 583 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. A Phase 1 Study to Assess the Relative Bioavailability of Two Capsule Formulations of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma. (7th August 2017) Authors: Hanley, Michael J.; Gupta, Neeraj; Venkatakrishnan, Karthik; Bessudo, Alberto; Sharma, Sunil; O'Neil, Bert H.; Wang, Bingxia; van de Velde, Helgi; Nemunaitis, John Journal: Journal of clinical pharmacology Issue: Volume 58:Number 1(2018) Page Start: 114 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Effect of a herbal extract containing curcumin and piperine on midazolam, flurbiprofen and paracetamol (acetaminophen) pharmacokinetics in healthy volunteers. (10th January 2013) Authors: Volak, Laurie P.; Hanley, Michael J.; Masse, Gina; Hazarika, Suwagmani; Harmatz, Jerold S.; Badmaev, Vladimir; Majeed, Muhammed; Greenblatt, David J.; Court, Michael H. Journal: British journal of clinical pharmacology Issue: Volume 75:Number 2(2013:Feb.) Page Start: 450 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Effect of blueberry juice on clearance of buspirone and flurbiprofen in human volunteers. (15th March 2013) Authors: Hanley, Michael J.; Masse, Gina; Harmatz, Jerold S.; Cancalon, Paul F.; Dolnikowski, Gregory G.; Court, Michael H.; Greenblatt, David J. Journal: British journal of clinical pharmacology Issue: Volume 75:Number 4(2013:Apr.) Page Start: 1041 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Effects of Strong CYP2C8 or CYP3A Inhibition and CYP3A Induction on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers. Issue 2 (9th July 2019) Authors: Tugnait, Meera; Gupta, Neeraj; Hanley, Michael J.; Sonnichsen, Daryl; Kerstein, David; Dorer, David J.; Venkatakrishnan, Karthik; Narasimhan, Narayana Journal: Clinical pharmacology in drug development Issue: Volume 9:Issue 2(2020) Page Start: 214 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Effects of Strong CYP3A Inhibition and Induction on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor: Results of Drug‐Drug Interaction Studies in Patients With Advanced Solid Tumors or Lymphoma and a Physiologically Based Pharmacokinetic Analysis. (11th August 2017) Authors: Gupta, Neeraj; Hanley, Michael J.; Venkatakrishnan, Karthik; Bessudo, Alberto; Rasco, Drew W.; Sharma, Sunil; O'Neil, Bert H.; Wang, Bingxia; Liu, Guohui; Ke, Alice; Patel, Chirag; Rowland Yeo, Karen; Xia, Cindy; Zhang, Xiaoquan; Esseltine, Dixie‐Lee; Nemunaitis, John Journal: Journal of clinical pharmacology Issue: Volume 58:Number 2(2018) Page Start: 180 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Mobocertinib Dose Rationale in Patients with Metastatic NSCLC with EGFR Exon 20 Insertions: Exposure–Response Analyses of a Pivotal Phase I/II Study. Issue 2 (29th May 2022) Authors: Gupta, Neeraj; Largajolli, Anna; Witjes, Han; Diderichsen, Paul M.; Zhang, Steven; Hanley, Michael J.; Lin, Jianchang; Mehta, Minal Journal: Clinical pharmacology & therapeutics Issue: Volume 112:Issue 2(2022) Page Start: 327 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Model‐Informed Drug Development for Ixazomib, an Oral Proteasome Inhibitor. Issue 2 (23rd March 2018) Authors: Gupta, Neeraj; Hanley, Michael J.; Diderichsen, Paul M.; Yang, Huyuan; Ke, Alice; Teng, Zhaoyang; Labotka, Richard; Berg, Deborah; Patel, Chirag; Liu, Guohui; van de Velde, Helgi; Venkatakrishnan, Karthik Journal: Clinical pharmacology & therapeutics Issue: Volume 105:Issue 2(2019) Page Start: 376 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Pharmacokinetics of ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment. (29th May 2016) Authors: Gupta, Neeraj; Hanley, Michael J.; Venkatakrishnan, Karthik; Perez, Raymond; Norris, Robin E.; Nemunaitis, John; Yang, Huyuan; Qian, Mark G.; Falchook, Gerald; Labotka, Richard; Fu, Siqing Journal: British journal of clinical pharmacology Issue: Volume 82:Number 3(2016:Sep.) Page Start: 728 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗